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Abstract
Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel
coronavirus strain. Some studies suggest that COVID-19 could be an
immune-related disease, and failure of effective immune responses in ini-
tial stages of viral infection could contribute to systemic inflammation
and tissue damage, leading to worse disease outcomes. T cells can act as a
double-edge sword with both pro- and anti-roles in the progression of
COVID-19. Thus, better understanding of their roles in immune
responses to SARS-CoV-2 infection is crucial. T cells primarily react to
the spike protein on the coronavirus to initiate antiviral immunity; how-
ever, T-cell responses can be suboptimal, impaired or excessive in severe
COVID-19 patients. This review focuses on the multifaceted roles of T
cells in COVID-19 pathogenesis and rationalizes their significance in elic-
iting appropriate antiviral immune responses in COVID-19 patients and
unexposed individuals. In addition, we summarize the potential therapeu-
tic approaches related to T cells to treat COVID-19 patients. These
include adoptive T-cell therapies, vaccines activating T-cell responses,
recombinant cytokines, Th1 activators and Th17 blockers, and potential
utilization of immune checkpoint inhibitors alone or in combination with
anti-inflammatory drugs to improve antiviral T-cell responses against
SARS-CoV-2.
Keywords: coronavirus; COVID-19; immune responses; SARS-CoV-2; T
cells.
INTRODUCTION
Coronavirus disease 2019 (COVID-19) is caused by a
novel strain of coronavirus, severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2).1 This latest viral
pandemic first surfaced in December 2019 and has since
spread aggressively with several millions of confirmed
cases, while mortality rates have claimed approximately
3.5% deaths of all infected cases globally.2 The close
genetic proximity of 2019-novel coronavirus (nCoV) with
SARS coronavirus assisted detection via probing for viral
nucleic acid,3-5 and initial reports revealed pneumonia-re-
lated pathogenesis in COVID-19 patients.6,7 Pre-existing
comorbidities and patient age have since been identified
as vital risk factors for case fatality rate (CFR) among
others, and multiple organ failure was observed in criti-
cally ill patients, who accounted for 5% of 72,314 cases,
with 49% CFR in China.8 Crucially, there are no proven/
approved direct antiviral therapies to treat COVID-19
patients, and therapeutic strategies revolve around sup-
portive care and treatment of disease symptoms only.
However, at present there are more than 2400 clinical tri-
als associated with COVID-19, investigating potential
therapeutic agents and strategies to tackle COVID-19.9
Coronaviruses are known to instigate diseases in
humans; OC43, 229E, NL63 and HKU1 classically infect
Abbreviations: ACE2, angiotensin-converting enzyme 2; ANG II, angiotensin II; CFR, case fatality rate; COVID-19, coronavirus
disease 2019; CTLs, cytotoxic T lymphocytes; DAMPs, damage-associated molecular patterns; SARS-CoV-2, severe acute respira-
tory syndrome coronavirus 2; E protein, envelope protein; ICs, immune checkpoints; ICIs, immune checkpoint inhibitors; M
protein, membrane protein; N protein, nucleocapsid protein; NLR, neutrophil–lymphocyte ratio; ORFs, open reading frames;
PAMPs, viral pathogen-associated molecular patterns; PRRs, pattern recognition receptors; RLRs, RIG-I-like receptors; S protein,
spike protein; Tex, T-cell exhaustion; TLRs, Toll-like receptors; Tregs, T regulatory cells
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upper respiratory tract, while Middle East respiratory syn-
drome coronavirus (MERS-CoV), SARS-CoV and SARS-
CoV-2 infect lower respiratory tract.1 SARS-CoV-2 gen-
ome comprises 14 open reading frames (ORFs) encoding
27 proteins, which include major structural proteins:
spike (S) protein, membrane (M) protein, envelope (E)
protein and nucleocapsid (N) protein.10 Angiotensin-con-
verting enzyme 2 (ACE2) is identified as the main host
cell receptor of SARS-CoV-2, responsible for allowing
viral entry into cells via interactions with its putative
ligand, S protein on the coronavirus.3 ACE2 is abun-
dantly expressed in lung epithelia;11 therefore, lungs are
the primary organs affected in COVID-19.12 ACE2 helps
to modulate the activity of angiotensin II (ANG II),
which elevates blood pressure and promotes inflamma-
tion.13 SARS-CoV-2 has a 10- to 20-fold higher binding
affinity with ACE2 compared with other SARS coron-
aviruses.14 Binding of SARS-CoV-2 with ACE2 dysregu-
lates ANG II signalling, leading to tissue injury.15
SARS-CoV-2 infection can initiate a potent immune
response, which includes immune activation and antiviral
immune responses via helper T cells (Th) and cytotoxic T
cells (CTLs),16 and induce infected cell death.17 However,
the transition between innate and adaptive immune
responses is crucial in determining disease outcomes of
SARS-CoV-2 infections; early immune responses primar-
ily have a protective role, whereas dysregulated and exac-
erbated inflammatory responses can fail in viral clearance
and lead to worse disease outcomes.16 Accumulation of
proinflammatory cytokines, lymphopenia and deviant T-
cell responses present evidence that COVID-19 might be
an immune-related disease. Moreover, antiviral immunity
is mediated by the generation of neutralizing antibodies
by plasma cells and CTL-mediated immunity, which
secrete cytokines/effector molecules for killing virus-in-
fected target cells. M immunoglobulins (IgM) provide
primary defence against viral infections, prior to the pro-
duction of high-affinity immunoglobulin G (IgG) for last-
ing systemic immunity, and therefore, their detection can
predict exposure times.18 However, impaired immune
responses, evident from the reduction in lymphocyte
levels (lymphopenia) and excessive cytokine release, lead
to tissue inflammation and damage in COVID-19
patients.19,20 Lymphopenia and/or T-cell exhaustion could
be one of the major causes of worsened clinical outcomes
in COVID-19 patients, whereas T-cell-mediated inflam-
mation and persistent activation of innate immune cells
could be contributing factors to lung pathology and sec-
ondary complications seen in severe cases.31,37,69 There-
fore, further understanding of the mechanisms by which
the immune response is activated upon SARS-CoV-2
infection, roles of innate and adaptive immunities during
the course of infection and the contribution of innate
and adaptive immune responses to disease recovery and
exacerbation is crucial for assigning therapeutic protocols
to patients, and the clinical application of pharmacologi-
cal drugs, which potentially can interfere with the host
immunity. The present review focuses on T cells, which
are at the forefront of all viral immune responses docu-
mented in COVID-19 patients, to highlight their anti-
and pro-roles in disease progression and present plausible
targets for therapeutic interventions.
IMMUNE CELLS IN THE LUNGS OF SARS-CoV-2-
INFECTED PATIENTS
Lungs are immensely affected by SARS-CoV-2 infection,
which leads to lesions with diffused alveolar damage
observed in non-surviving patients.21 SARS-CoV-2 infects
ACE2-expressing cells in the lungs such as type 2 alveolar
cells, leading to the dampening of antiviral IFN responses,
while the infiltration of adaptive immune cells in the
lungs can lead to heightened inflammatory responses
resulting in pulmonary oedema.22 Innate immune
responses against SARS-CoV-2 are initially prompted by
lung epithelial cells, alveolar macrophages and neu-
trophils, which then trigger adaptive immune responses
involving T and B lymphocytes.16 Ex vivo models showed
that SARS-CoV-2-infected pneumocytes and alveolar
macrophages prompted the release of proinflammatory
cytokines and antiviral IFN (type I and III) at low
levels.23,24
Lung autopsy from a COVID-19 case provided impor-
tant insights into the distribution of immune cell infil-
trates in the lungs; alveolar exudate showed moderate
levels of macrophages and low levels of neutrophils, while
interstitial compartment showed infiltration of T cells and
monocytes, but not B cells.25 Other post-mortem findings
from 38 patients who died with COVID-19 showed infil-
tration of macrophages in alveolar lamina and lympho-
cytes in pulmonary interstitium.26
Lymphopenia observed in the circulation of COVID-19
patients, particularly in those with severe disease, may
occur as a result of lymphocyte infiltration and sequestra-
tion in the lungs.27,28 Moreover, pulmonary influx of
immune cells could also potentially justify elevated neu-
trophil-to-lymphocyte ratios recorded in COVID-19
patients and presented as a biomarker for disease severity
and organ failure,28 due to imbalances in immune cell
infiltrates in the lungs; however, concrete evidence is war-
ranted to support it. Liao et al. analysed samples of bron-
choalveolar lavage fluid (BALF) from COVID-19 patients
and reported higher levels of macrophages and neu-
trophils, but lower levels of DCs and CD8+ T cells in
patients with severe disease compared to those with mod-
erate infection.29 Of interest, CD8+ T cells in BALFs from
patients with severe disease were more proliferative but
less clonally expanded compared to those with moderate
disease, implicating that CD8+ T-cell responses to SARS-
CoV-2 in severe cases could be compromised.29
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Moreover, the authors showed that patients with severe
disease have higher expression of activation and migra-
tory genes including GZMA, GZMK, ITGA1 and CXCR6
and higher levels of inflammatory cytokines including IL-
6, IL-8 and IL-1b in BALF, reflecting the hyperinflamma-
tory state in the lungs of these patients.29 Chua et al. per-
formed single-cell analyses of nasopharyngeal and
bronchial samples from COVID-19 patients and showed
that elevated ACE2 expression is correlated with IFNG
expression, and showed that these samples exhibit higher
expression levels of CCL2, CCL3, CCL20, CXCL10, IL8
and IL1B genes in patients with severe disease, which
could promote T-cell recruitment.30 These latter findings
demonstrated that epithelial cell/alveolar damage in
COVID-19 patients could be driven by the crosstalk
between epithelial and immune cells accompanied by a
proinflammatory environment, potentially giving rise to a
positive feedback loop that augments inflammation and
tissue destruction.30 In addition, the massive infiltration
of immune cells into the airways of COVID-19 patients
could significantly contribute to acute lung injury and
bacterial pneumonia.10
IMMUNE RESPONSES TO SARS-CoV-2
The arsenal of innate and adaptive immunity is mostly
capable of eliciting adequate antiviral immune responses
in mild and moderate cases of COVID-19 (Figure 1A).
Indeed, the co-ordination between innate and adaptive
immune responses during early stages of SARS-CoV-2
infection is essential to control viral dissemination.31
Moreover, adequate T-cell counts and sufficient T-cell
activation/clonal expansion have been recorded in
COVID-19 convalescent patients,32,33 implying the
importance of T-cell-mediated immunity in recovery
and disease resolution. T-cell-dependent protective roles
encompass systemic antiviral immune responses and Th-
cell-mediated activation of B cells, while CTLs have
prominent roles in the elimination of virus-infected
cells.34 Dendritic cells (DCs) and macrophages can
phagocytose virus-infected cells to initiate T-cell
responses via antigen presentation.35 Subsequently, CD4+
T cells stimulate B cells for the production of viral-
specific antibodies, and cytotoxic CD8+ T cells to target
virus-infected cells. In addition, recognition of viral
pathogen-associated molecular patterns (PAMPs), such
as viral RNA or damage-associated molecular patterns
(DAMPs) from host cells, by pattern recognition recep-
tors (PRRs), including RIG-I-like receptors (RLRs) and
Toll-like receptors (TLRs), initiates an inflammatory
response and leads to elevated secretion of inflammatory
cytokines and chemokines, such as interferon-gamma
(IFN-c), interleukin (IL)-6, monocyte chemo-attractant
protein-1 (MCP1) and C-X-C motif chemokine 10
(CXCL10).19
Excessive inflammatory innate responses together with
impaired adaptive immune responses can cause tissue
damage. Infection and lung damage trigger local immune
responses resulting in the recruitment of macrophages,
which prime adaptive T- and B-cell responses.1 Uncon-
trolled viral infection and high mortality rates in
advanced disease and severe cases of COVID-19 patients
resulting from delayed or insufficient activation of T-cell
responses may lead to severe lung damage or systemic
inflammation (Figure 1B). However, it is still unclear
whether the cytotoxicity observed in severe cases of
COVID-19 infection is caused exclusively by the hyperre-
activity of the adaptive immune response or by its sup-
pression.31 Moreover, in patients with severe COVID-19,
the total lymphocyte count was dropped to <1.5 9 109/L
with overall reduction of 0.31 9 109/L, compared with
non-severe patients.19 Lymphopenia has also been
observed in non-surviving COVID-19 patients, compared
with surviving patients.36 Therefore, lymphopenia could
be considered as a predictive biomarker for the severity
of COVID-19.19,37 Additionally, it is important to note
that T cells in some COVID-19 patients could be highly
activated,38 to mount potent immune responses, or may
exhibit functional exhaustion,39 indicating weaker
immune function, which subsequently results in worse
disease outcomes. However, functional studies are neces-
sitated to support these findings.
SARS-CoV-2 RECOGNITION BY T CELLS
Identification of recognizable proteins and epitopes of
SARS-CoV-2 is crucial to comprehend the reactivity of T
cells against SARS-CoV-2, and to evaluate T-cell
responses in infected individuals.40 Grifoni et al. predicted
SARS-CoV-2 epitopes, which can be recognized by T
cells, using bioinformatic approaches such as the Immune
Epitope Database and Analysis Resource (IEDB).40 Rama-
iah et al. identified eight T-cell epitopes distributed across
S (n = 2), E (n = 3) and M (n = 3) proteins, which are
recognized by all dominant HLA-DR alleles.41 This report
suggests that the subunit of vaccine comprising these
eight immunodominant epitopes may deliver appropriate
T-cell-mediated immune responses and development of
virus-specific antibodies.41 Additionally, Braun et al.
demonstrated that 83% of CD4+ T cells from SARS-CoV-
2 patients are spike (S)-reactive, which could target both
N- and C-terminal of S protein and coexpress CD38 and
HLA-DR.33 Grifoni et al. showed that 11-27% of total
CD4+ T cells responded against M, S and N proteins,
while CD8+ T cells responded against S and M proteins.40
Initially, it was reported that S protein of SARS-CoV-2
binds to human ACE2-expressing alveolar pneumocytes.42
Later studies confirmed that ACE2 is expressed only on
CD169+ macrophages in lymph nodes and spleen, and
not on T or B lymphocytes.43 These macrophages could
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recognize viral proteins including N and S proteins.39
These reports rationalize the importance of T-cell recog-
nition of SARS-CoV-2 proteins to elicit appropriate
immune responses to eliminate the virus.
T-CELL RESPONSES
T-cell responses to SARS-CoV-2 in COVID-19
patients
T-cell immune responses are considered highly specific
and have indispensable roles in eliciting potent antiviral
responses (Figure 1A). However, the magnitude of T-cell
responses in being beneficial or harmful for COVID-19
patients remains unclear due to evidences on their subop-
timal, dysfunctional or excessive activity.34 The presence
of highly activated and fully functional T cells in some
COVID-19 patients has been reported. A study by Weis-
kopf et al. demonstrated that SARS-CoV-2-specific CD4+
and CD8+ T cells are evident in the peripheral blood of
COVID-19 in the first 2 weeks after onset of symptoms.44
Additionally, authors demonstrated that the majority of
SARS-CoV-2-specific CD4+ T cells exhibited a central
memory phenotype with a dominant production of Th1
cytokines, while CD8+ T cells had a more effector pheno-
type with high levels of perforin expression.44 In another
study, it was reported that levels of CD38- and HLA-DR-
expressing memory CD4+ T cells and CD8+ T cells, and
CD4+PD-1+ memory T cells were higher in a proportion
of patients with severe COVID-19, compared with healthy
individuals.28,38 Importantly, the functionality of memory
CD8+ T cells and CD8+PD-1+CD38+ T cells in severe
COVID-19 patients was demonstrated by the high expres-
sion levels of perforin and granzyme B, compared with
those from healthy controls,33 implicating that PD-1 and
CD38 act as activation T-cell markers in COVID-19 cases.
Moreover, around two-thirds of COVID-19 patients
showed highly proliferative Ki-67+, non-na€ıve CD4+ and
CD8+ T cells, with similar levels of activation in both T-
cell subsets.38 Notably, both of these studies reported
heterogeneity in T-cell activation in COVID-19 patients
and provided evidence that both CD4+ and CD8+ T cells
are capable of mounting potent immune responses with
potential emergence of impaired or excessive T-cell
responses.
T cells are elevated in patients with mild COVID-19,
creating a robust antiviral immune response.29. In partic-
ular, CD8+ T cells express higher levels of cytotoxic mole-
cules such as granzyme A and FAS ligand, which are
beneficial in eliminating virus-infected cells.29 However,
in severe disease cases, the aforementioned cytotoxic
molecules were reduced due to the reduction in the
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Figure 1. T-cell responses against SARS-CoV-2. SARS-CoV-2 recognizes cells expressing ACE2 receptor including epithelial cells and macrophages.
In normal immune environment, infected epithelial cells degrade viral particles and present them to cytotoxic CD8+ T cells (CTLs). CTLs detect viral
protein through classical TCR-MHC I interaction, release cytotoxic granules, including granzyme B and perforin, and eliminate infected cells. Addi-
tionally, macrophages detect SARS-CoV-2 via ACE2 receptor and present the virus-derived peptides to CD4+ T cells (Th0) via TCR-MHC II interac-
tion. Once exposed to antigen, Th0 cells polarize primarily towards Th1, leading to the release of IFN-c to eliminate the virus, and Th2 to trigger
humoral-mediated immune responses and antibody secretion against SARS-CoV-2 virus (A). In incompetent immune environment, SARS-CoV-2
recognizes epithelial cells or macrophages via ACE2 receptor. Viral RNA will replicate by hijacking the host transcriptional machinery. These viral
progenies will infect multiple cells leading to tissue damage and further lethal complications. In these circumstances, CD4+ and CD8+ T cells fail to
provide adequate cell/humoral-mediated immune responses to eliminate viral-infected cells. On the other hand, Th0 cells are primed towards Th17
phenotype, resulting in the inhibition of Th1-mediated immune responses (B). In COVID-19, T cells could be exhausted and could overexpress
exhaustion markers including PD-1, CTLA-4, TIM-3 and TIGIT through unknown mechanisms . In severe COVID-19 cases, the production of
cytokines, including IL-1b, IL-6, IL-2, IL-10 and TNF-a, is increased leading to the generation of cytokine storm, which induces further unfavourable
outcomes and may eventually lead to lymphopenia (B).
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proportion of CTLs.29 Studies on phenotypical characteri-
zation of CD4+ and CD8+ T cells showed that similar
percentages of na€ıve, central memory and effector CD4+
T cells were detected in COVID-19 patients and healthy
controls. However, the percentages of both na€ıve and cen-
tral memory CD8+ T cells were lower in COVID-19
patients 45. Additionally, percentages of terminally differ-
entiated effector CD4+ and CD8+ T cells were higher in
COVID-19 patients, compared with healthy controls.45
Notably, the levels of regulatory T cells (Tregs) in severe
COVID-19 patients were lower than those of mild cases.46
Together, these dysregulations in the balance of T-cell
subsets, including Tregs, Th1, na€ıve and memory T cells,
could contribute to severe inflammatory conditions, and
perhaps lead to COVID-19 relapse.47,48
Apart from conventional T cells, Rijkers et al. reported
that a special group of cd T cells, Vc9Vd2, were markedly
decreased in non-surviving patients, compared with
healthy or surviving COVID-19 patients at the time of
hospital admission.49 Altogether, these reports rationalize
the significance of T cells to elicit appropriate antiviral
responses against SARS-CoV-2 infection and present
them as potential prognostic biomarkers.
Although early antiviral responses mediated by CD4+
and CD8+ T cells are most likely to be protective, the
effectual innate immune evasion capabilities of SARS-
CoV-2 make T cells difficult to generate efficient antiviral
responses by limiting IFN type I and III responses.50
Importantly, it has also been reported that during the
course of COVID-19 progression, late T-cell responses
might amplify other pathological disease outcomes.51 Sev-
eral clinical trials (NCT04340921, NCT04410432,
NCT04403880, NCT04401436, NCT04351711,
NCT04403061 and NCT04365166) have been registered
to characterize T-cell phenotypes and measure T-cell-
derived cytokines in COVID-19 patients with different
disease phases (symptomatic, mild and severe) in order to
evaluate the contribution of T-cell-mediated immunity to
disease outcomes, including secondary complications such
as myocarditis.
T-cell responses in COVID-19 convalescent patients
and unexposed healthy individuals
Restoration of T-cell counts in recovered patients could
provide important insights into the role of T cells in
antiviral responses. SARS-CoV-2-specific T cells were pre-
sent in more than 70% of COVID-19 convalescent
patients.40 Grifoni et al. quantified the SARS-CoV-2-
specific CD4+ and CD8+ T cells and found that 100%
CD4+ T cells and 70% CD8+ T cells have SARS-CoV-2
spike-specific responses in recovered patients.40 Func-
tional assays confirmed that CD4+ T cells appeared as
Th1 phenotype and produced substantial amount of IFN-
c and expressed lower levels of IL-4, IL-13, IL-5, or IL-
17A against S protein.40 Likewise, the majority of SARS-
CoV-2 spike-specific CD8+ T cells produced IFN-c and
the vast majority of IFN-c+CD8+ T cells also coexpressed
granzyme B and tumour necrosis factor-alpha (TNF-a).40
These data suggest that the majority of CD4+ and CD8+
T cells in recovered patients generated substantial antivi-
ral immune responses against S protein, implicating the
importance of functional T cells in viral clearance and
recovery. Moreover, these data rationalize the significance
of utilizing SARS-CoV-2 S protein as a key candidate for
vaccine generation.
Incidentally, SARS-CoV-2-reactive T cells have also
been found in unexposed healthy individuals,33,40 possi-
bly due to previous exposure, residual immunity and/or
close genetic proximity of SARS-CoV-2 with other coro-
naviruses. A study on T-cell responses against S and M
proteins of SARS-CoV-2 in unexposed individuals and
asymptomatic or mild/severe COVID-19 convalescent
patients showed that highest T-cell responses were
observed in severe convalescent patients and lowest in
asymptomatic and unexposed individuals.52 Furthermore,
compared with antibody-sero-positive individuals, detect-
able T-cell responses were observed in antibody-sero-
negative individuals, albeit at lesser frequency.52 Finally,
authors concluded that asymptomatic/mild COVID-19
convalescent patients could generate a robust and dur-
able memory T-cell responses to prevent recurrent infec-
tions, even though in the absence of concurrent humoral
responses.52 In concordance with this study, it has been
reported that asymptomatic patients show weaker
immune responses, compared with symptomatic individ-
uals, and considerable percentage of symptomatic
patients showed reduced amount of neutralizing anti-
body at the early stages of convalescence.53 COVID-19
convalescent patients also showed a strong correlation
with neutralizing antibody titre against human ACE2
and virus-specific T-cell counts in 2 weeks post-hospital
discharge.47
COVID-19 PATHOPHYSIOLOGICAL AND
IMMUNOLOGICAL FEATURES
Acute respiratory distress syndrome (ARDS) is the pri-
mary complication of SARS-CoV-2 infection.1,54 SARS-
CoV-2 infection causes diffused alveolar damage in the
lung and damage in the hyaline membrane in alveoli,
leading to interstitial widening and oedema and resulting
in difficulty in breathing.55 ARDS causes respiratory fail-
ure that caused 70% , while sepsis contributed to approx-
imately 28% of COVID-19-related fatalities.1 Moreover,
about 17% of the patients recovering from COVID-19
disease have fibrous stripes, indicating that the lesions are
developed during the chronic pulmonary inflammation.56
Inflammation of pulmonary endothelial cells (endothe-
liitis) is one of the contributing factors to the initiation
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and progression of ARDS by altering the integrity and
function of the vascular barrier.57 The mechanisms
underlying these pathological changes are associated with
increased vascular permeability, binding of SARS-CoV-2
virus to ACE2 receptors, recruitment of activated neu-
trophils, macrophages and other immune cells, and
increased production of inflammatory cytokines 57,58.
Some of these cytokines further amplify the inflammatory
loop and induce the recruitment of more inflammatory
cells, while other cytokines initiate and activate the coag-
ulation cascade.57 The resultant intense immune response
is extensively documented in ARDS affecting lungs, but
leads to multiorgan dysfunction (MODS) failure via tissue
damage and ultimately death in severe SARS-CoV-2
infections.
A wide range of secondary complications have been
associated with SARS-CoV-2 infection, including venous
thromboembolism,59 cardiovascular complications,60
acute liver and kidney injury,61,62 neurological complica-
tions,24,53,63 immune thrombocytopenia,64,65 secondary
infection,19,66 septic shock,19,67 acute respiratory fail-
ure,62,68,69 disseminated intravascular coagulation
(DIC)70,71 and cytokine release syndrome.72-74 These sec-
ondary complications may result from uncontrolled viral
dissemination leading to systemic cytokine storm and
excessive inflammation.75. In this section, we focus pri-
marily on disease mechanisms or complications of
COVID-19 caused either by hyperactivated T cells or by
insufficient T-cell responses.
Cytokine storm
‘Cytokine storm’ refers to the plethora of proinflamma-
tory cytokines and chemokines detected in various patho-
logical conditions, and is one of the key pathological
features observed in SARS-CoV-2-infected patients.36,73
High cytokine levels have been recorded in critically ill
COVID-19 patients.19 Various immune cell types, includ-
ing macrophages, neutrophils, DCs, and NK, B and T
cells, can contribute to cytokine storm and the hyperacti-
vation state of the inflammatory response in COVID-19
patients.20
TNF-a, IL-6 and IL-1b, principally released by innate
immune cells, can be one of the major driving forces for
cytokine release syndrome and severe systemic inflamma-
tory responses in patients with advanced stages of SARS-
CoV-2 infection,76-79 and some of them could be one of
the underlying mechanisms responsible for lymphopenia
and/or inadequate Th1 responses in these patients.39,80 It
was also reported that elevated serum levels of TNF-a
and IL-6 were negatively correlated with the total T-cell
count in severe cases of COVID-19, indicating the poten-
tial involvement of these cytokines in lymphopenia and
T-cell loss.39 Conversely, patients in the recovery phase
had a marked reduction in serum levels of the
aforementioned cytokines and showed a restoration of T-
cell count.39 In light of these findings, it was proposed
that IL-6 blockers, such as sarilumab, siltuximab and toci-
lizumab, and IL-1b receptor blocker can have therapeutic
efficacy in treating severe cases of COVID-19 patients to
resolve hyperinflammation and control the propagation
of the pathological immune response to virus infec-
tion.78,81,82 However, the therapeutic efficacy and safety
of IL-6 and IL-1b blockers in COVID-19 patients are cur-
rently under clinical investigations.9
Elevated levels of chemokines and cytokines, such as
CCL2/3/5, CXCL8/9/10 and IFN-c, TNF-a, IL-1b, IL-
1RA, IL-6, IL-7, IL-8, IL-12, IL-33, granulocyte/granulo-
cyte-macrophage colony-stimulating factors (G-CSF and
GM-CSF), vascular endothelial growth factor A (VEGFA)
and platelet derived growth factor subunit B (PDGFB),
facilitate the recruitment of other leukocytes to tissues
and promote effector functions leading to severe ARDS
and tissue damage (Figure 1B).77,83 Furthermore, Th17-
derived cytokines have been implicated in the excessive
lung pathology observed in ARDS patients,84 potentiating
their contribution to ARDS in COVID-19 patients,45 and
rationalizing the potential therapeutic benefits of targeting
Th17 cytokines (discussed in the next Section).
T-cell activation or exhaustion
T-cell-mediated adaptive immune responses are essential
for viral clearance and long-term antiviral immunity, but
may contribute to cytokine storm and could be compro-
mised in severe cases of COVID-19 patients due to T-cell
exhaustion.31,39,75 Thus, T cells execute antiviral activities
or contribute to tissue inflammation or damage, depend-
ing on the host immune response activation status.85 It
has been suggested that the signature cytokine storm of
COVID-19 may promote Th17-induced vascular leakage
and permeability.86 Elevated cytokine levels lead to
autoimmune and inflammatory responses that influence
the development of ARDS. Activated CD8+, Th1, Th17,
NK and NKT cells together with other innate immune
cells secrete additional cytokines to target virus-infected
cells, and their overstimulation together with effector
innate immune cells may lead to tissue damage.84
T cells can express high levels of inhibitory immune
checkpoints such as PD-1, TIM-3, CTLA-4 and TIGIT
upon activation.87 On the other hand, sustained expres-
sion of inhibitory immune checkpoints in response to
persistent antigen stimulation can lead to progressive loss
of effector functions; a state known as T-cell exhaustion
and has been observed in severe viral infections.88,89
There is evidence suggesting that T cells in COVID-19
patients could have an exhausted phenotype, indicated by
the overexpression of inhibitory immune checkpoints and
reduced expression levels of genes encoding cytokines and
cytolytic molecules.39,90,91 However, the impact of
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immune checkpoint overexpression on T-cell effector
function, and T-cell capacity of proliferation and viral
clearance has not been elucidated in COVID-19 patients.
High proportions of both activated CD4+HLA-
DR+CD38+ T cells and CD4+PD-1+CD57+ exhausted or
senescent T cells were detected in COVID-19 patients,
compared with healthy control patients.45 Zheng et al.
demonstrated that CD4+ T cells with low levels of IFN-c,
IL-2 and TNF-a were higher in severe COVID-19
patients, compared with healthy controls and mild
patients.90 Moreover, CD8+ T cells expressing high levels
of PD-1, CTLA-4, TIGIT, granzyme B and perforin were
increased in the severe group, compared with the mild
group.90 These data suggest that SARS-CoV-2 infection
may lead to the functional impairment in CD4+ T cells
and uphold excessive activation of CD8+ T cells. More-
over, the frequency of CD8+PD-1+CTLA-4+TIGIT+ T cells
in the circulation of patients with severe COVID-19
infection was higher than that of mild cases,90 suggesting
the potential of their exhaustion (Figure 1B). In another
study, it was reported that NK cells and CD8+ T cells of
SARS-CoV-2 patients have higher expression of NK cell
inhibitory receptor, NKG2A, characterized by reduced
intracellular levels of CD107a (degranulation marker), IL-
2, IFN-c, TNF-a and granzyme B, indicating the func-
tional impairment of NK and CD8+ T cells in these
patients.91 While these studies provide evidence of
immune checkpoint overexpression on T cells from
COVID-19 patients, particularly those with severe cases,
further studies are warranted to determine whether this
occurs as a result of T-cell activation or exhaustion.
THERAPEUTIC APPROACHES TO IMPROVE T-CELL
RESPONSES IN COVID-19 PATIENTS
There are potential therapeutic approaches, which can be
used for COVID-19 treatment, such as antivirals, anti-
bodies targeting SARS-CoV-2 proteins and antibodies
from recovered COVID-19 patients. However, in this
review we will focus on therapeutic approaches, which
are directly or indirectly related to T-cell responses, T-
cell-derived cytokines and the potential combined thera-
pies aimed at improving virus-specific T-cell responses,
Th1 responses, expanding T-cell counts, reversing T-cell
exhaustion and settling inflammation. Clinical trials that
have been designed to assess the safety and efficacy of
several therapeutic strategies aiming to improve T-cell
responses against SARS-CoV-2 infection are listed in
Table 1.
Adoptive T-cell therapy against COVID-19
Building on decades of old knowledge of adoptive T-cell
therapies in various pathological conditions including
viral infections, utilization of virus-specific T cells against
SARS-CoV-2 seems a logical therapeutic approach for
treating COVID-19. Autologous or allogeneic viral-speci-
fic T cells can be expanded in vitro and infused to restore
effective antiviral immunity, and have shown efficacy in
treating various viral infections.92 SARS-CoV-2-specific T
cells can be isolated from circulation of convalescent
donors and expanded using SARS-CoV-2-derived pep-
tides and exploited for treating severe cases of COVID-19
(Figure 2A). However, the efficacy, treatment-related toxi-
cities and challenges associated with utilization of adop-
tive T-cell therapy have limited its use in COVID-19.
Importantly, it is not possible to utilize unmatched allo-
genic T cells due to the genetic restrictions (HLA class I),
and in vitro-expanded T cells by prolonged stimulation to
achieve required cell yields could exhibit functional
exhaustion or transferred T cells could in turn contribute
to cytokine storm, leading to disease complications of
COVID-19.93 However, a clinical trial based on novel
adoptive T-cell therapy for COVID-19 is ongoing
(NCT04351659), while another planned clinical trial will
adapt an innovative approach of utilizing already-col-
lected SARS-CoV-2-specific T cells from recovered
patients to treat COVID-19 patients with high risk of res-
piratory failure (NCT04401410) (Table 1). Another thera-
peutic strategy that has been proposed to improve
antiviral Th1 responses is based on the use of SARS-CoV-
2-specific T cells with IFN-c exosomes; clinical trial has
been registered to test efficacy in COVID-19 patients
(NCT04389385) (Table 1).
SARS-CoV-2 vaccines activating T-cell responses
The rapid availability of complete genome of SARS-CoV-
2 led to identification of numerous candidates for vaccine
development, and the role of T cells in vaccine-mediated
immunity is unprecedented due to the generation of
effector and memory T cells following stimulation of
na€ıve T cells.93 Interestingly, SARS-CoV-2-reactive T cells
were found in around 40-60% of unexposed healthy indi-
viduals,33 which suggested the presence of cross-reactive
T cells and passive immunity in general populations. Suc-
cessful vaccines should generate SARS-CoV-2-reactive T
cells with high specificity for potent immune responses
devoid of the undesired effects of inflammation or incep-
tion of disease.
S protein of SARS-CoV-2 is identified as the most suit-
able target for vaccine development to trigger virus-speci-
fic T-cell responses and humoral immune responses.94
The adenovirus-based viral vector vaccine expressing S
protein, adenovirus type-5 (Ad5-nCoV), is among the
pioneering viral vaccines designed to tackle COVID-1995
(Figure 2B). Zhu et al. reported the safety and tolerability
of administering a single dose of adenovirus type 5-vec-
tored COVID-19 (Ad5-nCoV) vaccine in healthy individ-
uals (NCT04313127), and its success in producing
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specific antiviral T-cell and humoral immune responses
after 2 weeks of administration.96 Of note, there was a
marked increase in the production of IFN-c, TNF-a and
IL-2 by CD4+ and CD8+ T cells post-vaccination.96 Two
additional clinical trials testing Ad5-vectored COVID-19
vaccines are also registered (NCT04398147 and
NCT04341389). In addition, vaccines based on DCs or
artificial APCs modified with lentiviral vector expressing
synthetic SARS-CoV-2 proteins will be also tested in clin-
ical trials (NCT04276896 and NCT04299724)95 (Table 1).
mRNA-based vaccine, encoding SARS-CoV-2 antigen
(S protein) to be administered via liposomal delivery
system, has been developed by Moderna, and it is under
clinical investigation (NCT04283461) to assess its safety
and efficacy in COVID-19 patients9,97 (Figure 2B,
Table 1). The advantages of using mRNA vaccines include
the mimicking of natural viral infection and their safe use
as they contain only a short synthetic version of the viral
mRNA, which encodes only the antigen protein, and it
cannot be integrated into the host chromosomes. Hence,
mRNA-based vaccines are safer than protein-based vacci-
nes as there are no potential risks associated with virus
reactivation. Studies from animal models showed the
potential benefits of using newly developed DNA-based
Table 1. Therapeutic strategies to improve antiviral T-cell responses and resolve systemic inflammation in COVID-19.
Therapeutic strategy Drug/inhibitor Clinical trial number Potential benefits Ref.
Adoptive T-cell transfer
(SARS-CoV-2-reactive T cells)
SARS-CoV-2-reactive T-cell-
derived IFN-c exosomes
- NCT04351659
NCT04401410
NCT04389385
Improved specific antiviral T-cell responses against
SARS-CoV-2
9
Viral vector-based vaccines
mRNA-based and DNA-based
vaccines
- NCT04313127
NCT04398147
NCT04341389
NCT04276896
NCT04283461
NCT04336410
Improved specific antiviral T-cell responses against
SARS-CoV-2 and production of IFN-c
9,101
Recombinant IL-7 CYT107 NCT04407689
NCT04379076
NCT04426201
Restored T-cell count and reverse lymphopenia
Enhanced TCR repertoire diversity and generation of
memory CD8+ T cells
Improved trafficking of T cells to infection site
9
Low dose of recombinant IL-2 ILT101 NCT04357444 Expansion/activation of Tregs to control excessive
inflammation
Expansion of other T-cell subsets, including effector
cells
9
Th1 activators IFN-b1b (Ziferon) NCT04343768 Improved symptoms
Activated Th1 response
Viral clearance
Ameliorated inflammation induced by cytokine
storm
113
Th17 blockers Anti-IL-17, IL-17R
and anti-IL-23
N/A 114
JAK2 inhibitor Fedratinib N/A 114
ICIs Anti-PD-1
(pembrolizumab or
nivolumab)
NCT04268537
NCT04333914
NCT04356508
NCT04413838
Reversal of T-cell exhaustion
Restored effector T-cell function
9,120
Figure 2. Therapeutic strategies to restore SARS-CoV-2-specific T-cell immune responses. Autologous (from a COVID-19 patient) or allogeneic
(from a recovered patient), peripheral blood mononuclear cells (PBMCs) can be cultured in the presence of SARS-CoV-2-derived peptides, IL-2,
GM-CSF or possibly other cytokines to enhance the function of antigen-presenting cells, enrich T cells and enhance the generation of activated
viral-specific T cells, which can be infused back into a COVID-19 patient. This could restore effective antiviral T-cell immunity, and result in
beneficial clinical outcomes (A). The use of viral vector-based, mRNA-based or DNA-based vaccines expressing the S protein of SARS-CoV-2 can
lead to the activation of virus-specific CD4+ and CD8+ T cells via antigen-presenting cells, followed by the activation of B cells and secretion of
antibodies by plasma cells (B). In COVID-19 patients, the administration of recombinant IL-7 could enhance T-cell receptor repertoire diversity,
promote the capacity of T-cell trafficking to the lungs and alleviate lymphopenia leading to enhanced antiviral immune response. Low-dose
recombinant IL-2 could control ARDS and excessive inflammation by expanding and activating Tregs, and possibly increase the level of effector
CD4+ and CD8+ T cells as they express IL-2 receptor. Additionally, administration of interferons could also help in viral clearance and improving
antiviral T-cell responses (C).
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vaccines targeting SARS-CoV-2 antigens in inducing T-
cell responses characterized by levels of IFN-c secreted by
CD8+ and CD4+ T cells, along with humoral immune
responses98,99 (Figure 2B, Table 1). The safety, clinical
efficacy and immunogenicity of a DNA vaccine named
INO-4800, carrying the DNA fragment of the S protein,
will be investigated in phase 1/2 clinical trial, involving
healthy individuals, in China and South Korea
(NCT04336410)100,101
IL-7 and Low dose of IL-2 to restore the repertoire of
T cells
IL-7 can enhance T-cell receptor repertoire diversity,102
promote the capacity of T-cell trafficking to infection
sites,103 induce the proliferation of na€ıve and memory T
cells and increase the circulating pool (CD4+ and CD8+ T
cells).104,105 On these grounds, clinical trials to evaluate
the efficacy of recombinant IL-7 to restore lymphocyte
counts in COVID-19 patients have been registered
(NCT04407689, NCT04379076 and NCT04426201) (Fig-
ure 2C, Table 1). The administration of low-dose recom-
binant IL-2 in COVID-19 patients has been proposed as
an alternative therapeutic strategy to control ARDS and
excessive inflammation by expanding and activating
Tregs; a clinical trial has been registered (NCT04357444)
(Figure 2C, Table 1). IL-2 is a growth factor and impor-
tant cytokine for the survival and proliferation of Tregs
and T effector cells,106,107 and therefore administrating
low doses of recombinant IL-2 in COVID-19 patients
should resolve lymphopenia and restore normal T-cell
counts. The safety of using low dose of recombinant IL-2
and its efficacy in expanding and activating Tregs in
patients with autoimmune diseases have been
reported.108-110
Th1 activators (IFNs) and Th17 blockers (anti-IL-17,
anti-IL-17R and anti-IL-23)
It has been suggested that activated potent adaptive
immune responses during early disease stages may corre-
late with improved clinical outcomes. One case report by
Thevarajan et al. showed evidence suggesting that the
recruitment of immune cells, including activated CD4+
and CD8+ T cells, follicular T helper cells and plasma
cells secreting IgG and IgM antibodies against SARS-
CoV-2 virus in the blood of a patient with symptomatic
non-severe case of COVID-19 infection, precedes disease
resolution and recovery.111. Furthermore, low serum
levels of proinflammatory cytokines and chemokines,
such as IFN-c, IL-6, IL-8 and MCP-1, were observed in
the patient, when symptoms were evident,111 suggesting a
potential relationship between symptom development and
inadequate immune responses. Thus, sufficient activation
of immune response, in particular adaptive immune
response, for adequate cytokine production, including
IFN-a/b/c, IL-12 and IL-15, is crucial for viral clearance
and symptomatic recovery.112
A study by Kuppalli et al. demonstrated that severe
COVID-19 disease is associated with elevated levels of IL-
6, reduced levels of CD8+ T cells, suppressed Th1 antivi-
ral responses and increased levels of IL-10, suggesting that
cytokine storm together with suppressed Th1 antiviral
adaptive responses may lead to severe COVID-19.80 On
this basis, a randomized controlled clinical trial to test
the clinical efficacy and safety of the administration of
IFN-b1 and IFN-b2 in moderate-to-severe COVID-19
patients has been designed (NCT04343768) (Figure 2C,
Table 1).113
Targeting Th17 responses could offer another therapeu-
tic strategy for treating severe COVID-19 patients, with a
predominant Th17 immune profiles and complications
associated with cytokine storm.86,114 IL-17A can augment
the release of proinflammatory cytokines by innate
immune cells, including GM-CSF, IL-23, IL-1b and IL-6,
and propagate lung pathology during ARDS,115 and its
blockade was beneficial in ameliorating lung inflamma-
tion in murine models116 and myocarditis,117 which is
one of the major causes of high mortality rates in
COVID-19 patients.86 Thus, targeting Th17 responses via
antibodies targeting IL-17, IL-17R and IL-12/23p40 or
Janus kinase (JAK2)-specific inhibitor (which does not
interrupt IFN signalling) could be used as future thera-
peutic approaches to minimize immunopathology caused
by cytokine storm without interfering with Th1 response
in cases of severe COVID-19114 (Table 1).
Immune checkpoint inhibitors
As mentioned above, SARS-CoV-2 infection may induce
T-cell exhaustion by increasing the expression of inhibi-
tory immune checkpoints (ICs),39,90,91 leading to loss of
effector T-cell functions including viral clearance. Impor-
tantly, elevated PD-1 and TIM-3 expressions were
recorded in COVID-19 patients who developed symp-
tomatic disease from prodromal stages.39 Therefore, tar-
geting ICs could have therapeutic potentials in COVID-
19 patients, in particular those with compromised adap-
tive immune responses including Th1 responses and cyto-
toxic CD8+ T-cell response. However, such interventions
may only benefit patients with initial to intermediary dis-
ease states as T-cell exhaustion in critical patients could
be irreversible.118 Up to date, the effect of IC inhibitors
(ICIs) on disease symptoms and clinical outcomes in
COVID-19 patients has not been evaluated. In the setting
of other viral infections, the efficacy of anti-PD-1 (pem-
brolizumab) has been evaluated in a small cohort of
patients with John Cunningham virus infection.119 Tar-
geting PD-1 and possibly other ICs in COVID-19 patients
could be beneficial in releasing the brake of T-cell
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exhaustion to induce more potent and sustained antiviral
responses mediated by effector T cells and cytotoxic
CD8+ T cells, and the development of functional memory
T cells for long-term immunity.89,120
Four clinical trials have been designed to assess the
safety and therapeutic efficacy of anti-PD-1 monoclonal
antibody (mAb) in patients with COVID-19
(NCT04268537, NCT04333914, NCT04356508 and
NCT04413838) (Table 1). However, findings from pre-
clinical models showed that targeting PD-1/PD-L1 axis
could result in excessive inflammation and tissue dam-
age.121,122 There is a possible risk of immune-related
adverse events (irAEs) and uncontrolled activation of
immune cells associated with the use of ICIs, in particular
those targeting PD-1/PD-L1, which rarely cause life-
threatening or fatal complications, such as myocarditis
and pneumonitis.123
To avoid any potential risks of severe inflammation124
and obtain effective clinical outcomes, it would be ideal
to combine anti-PD-1 mAb with other treatments, which
minimize the immunopathology caused by cytokine
storm, such as anti-IL-6 receptor mAb or anti-IL-1 recep-
tor mAb.81,125 Clinical trials have been planned to evalu-
ate the safety and efficacy of these anti-inflammatory
treatments. Therefore, it is encouraging to examine the
effect of combined therapy, anti-PD-1 with anti-IL-6R or
anti-IL-1 receptor mAbs in COVID-19 patients. To assess
the potential benefits of suppressing the hyperinflamma-
tory state on disease outcomes, clinical trials have been
registered and planned to evaluate the safety and thera-
peutic efficacy of using IL-6 and IL-1 blockers or Bru-
ton’s tyrosine kinase (a key signalling pathway in
macrophage activation and cytokine production) small
molecule inhibitor in severe COVID-19 patients.9,81,125-127
However, precautions are required during the assignment
of therapeutic protocols, which simultaneously target PD-
1 and IL-6 signalling pathways, and the time course of
COVID-19 infection is an important factor that should
be considered and could predict the response to therapy.
Early therapeutic interventions to block IL-6 signalling
during the early phase of disease, for example in patients
with mild symptoms, may have detrimental effects and
may result in insufficient adaptive and innate immune
response required for viral clearance. On the other hand,
late therapeutic interventions to block both PD-1 and IL-
6 signalling pathways in ICU COVID-19 patients and sev-
ere cases may have better clinical outcomes associated
with T-cell exhaustion reversal and reduced tissue damage
and systemic inflammation.39,81,128 Overall, these
approaches aim to stimulate antiviral immunity and pre-
vent secondary complications of SARS-CoV-2 infection,
which include sepsis and ARDS onset, concomitant with
T-cell depletion and elevated inflammatory cytokine
release.
FUTURE DIRECTIONS
Despite the devastating global impact of COVID-19, there
is no proven specific antiviral therapy in clinical use at
present and treatment regimens mainly involve palliative
therapies for treating comorbidities.3 COVID-19 treat-
ment requires a deep understanding of immune responses
during the course of disease, in particular T-cell
responses, which exhibit a protective role at early stages
of disease but could also contribute to the onset of fatal
comorbidities. Appropriate control of SARS-CoV-2 infec-
tion and disease management require a timely therapeutic
intervention to target inflammation and prevent disease
worsening and secondary complications in severe cases.
Early therapeutic interventions to block proinflammatory
cytokines in patients with mild symptoms may have
detrimental effects and result in insufficient immune
response and impaired viral clearance. On the other hand,
late therapeutic interventions to revert T-cell exhaustion
and ameliorate hyperinflammatory response in critical
COVID-19 patients may have better clinical outcomes.
Various therapeutic strategies and vaccines have been
proposed and will be investigated in different clinical trials.
These include T-cell adoptive transfer therapy, viral vector-
, nucleic acid-, protein- and DC-based vaccines comprising
of autologous DCs primed with specific viral antigens, and
GM-CSF could be useful to boost antiviral immunity and
specific T-cell responses. A potential self-adjuvanting
approach on vaccine production using multiple antigenic
peptides is imperative to induce broad antiviral responses
including adequate antibody production and T-cell-medi-
ated immune responses against SARS-CoV-2. Additionally,
cytokine therapies such as the administration of recombi-
nant IL-7 and low dose of IL-2 could be beneficial in
restoring T-cell counts and expanding Tregs in COVID-19
patients, especially in those with severe disease to control
excessive inflammatory response. Furthermore, blocking
cytokines to skew T-cell induction towards Th1 responses
via antibodies targeting cytokines such as IL-10 and IL-4
could result in favourable outcomes.129,130 The blockade of
TGF-b, which could be released by T-cell subsets, in partic-
ular Tregs, in COVID-19 patients could also serve as future
therapeutic approach to prevent excessive oedema, neu-
trophil recruitment to the lung and fibrosis in the lungs.131
Moreover, combined blockade of ICIs with anti-inflamma-
tory drugs could be beneficial in preventing the occurrence
of potential risks associated with severe immune-related
adverse events.
Developing a TCR database using high-throughput
TCR sequencing on mild, severe, deceased and recovered
COVID-19 cohorts would be beneficial to quantify patho-
gen-specific TCR repertoire with potential diagnostic/
prognostic values. Additionally, studies focusing on
SARS-CoV-2 reconstruction using genetic engineering
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platforms would be beneficial to understand the immune
responses and downstream viral targets. Furthermore,
identifying specific SARS-CoV-2 targets to develop antivi-
ral agents and biomarkers to predict the clinical response
to therapy would benefit disease management.
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